In this week's episode we’ll learn more about the use of ruxolitinib plus dexamethasone to treat newly diagnosed patients with adult hemophagocytic lymphohistiocytosis; lysine-specific demethylase-1 inhibitors as a potential new class of therapies for sickle cell disease and other beta-globinopathies; and insights into clinical characteristics of patients with von Willebrand factor levels that are lower than normal but higher than those typically used to diagnose von Willebrand disease.
Featured Articles:
View all episodes
By American Society of Hematology
4.1
4848 ratings
In this week's episode we’ll learn more about the use of ruxolitinib plus dexamethasone to treat newly diagnosed patients with adult hemophagocytic lymphohistiocytosis; lysine-specific demethylase-1 inhibitors as a potential new class of therapies for sickle cell disease and other beta-globinopathies; and insights into clinical characteristics of patients with von Willebrand factor levels that are lower than normal but higher than those typically used to diagnose von Willebrand disease.
Featured Articles:
140 Listeners
324 Listeners
27 Listeners
507 Listeners
87 Listeners
1,120 Listeners
2 Listeners
196 Listeners
362 Listeners
2 Listeners
1 Listeners
29 Listeners
181 Listeners
48 Listeners
3 Listeners